Chongqing printed the "14th Five-Year Plan" for the pharmaceutical industry
Time of Update: 2023-02-01
Among them, in terms of accelerating the upgrading of the industrial chain structure, it is necessary to increase innovation investment in key areas such as antibodies, recombinant proteins and peptide drugs, vaccines, and cell therapy to accelerate the development of the biopharmaceutical industry; Vigorously develop characteristic APIs, high-quality generic drugs, high-end preparations, and clinical shortage drugs, and improve the technical level of the chemical drug industry.
Lilly CIIE joined hands with Ader Biologics and Ranshi Medical to help the new development of precision diagnosis and treatment of cancer in China
Time of Update: 2022-11-14
On November 6, at the 5th CIIE, Lilly reached a cooperation intention with Ader Biologics and Ranshi Medical to jointly promote the development of Lilly's world's first highly selective RET inhibitor, septitinib, for companion diagnostics in China, so as to benefit more RET-driven cancer patients in China.
FDA updates the Pharmaceutical Manufacturing Inspection Compliance Manual with remote assessments and examples of advanced quality system indicators
Time of Update: 2022-10-02
On September 16, the U. S. FDA published two Important Compliance Program Manuals (CPGMs) for pharmaceutical production inspections and pre-approval inspections. The revision is significant, mainly d
Oral COVID-19 drug outbreak! How much is known about RdRp inhibitors
Time of Update: 2022-09-14
Following the approval of Azfedine as the first domestic COVID-19 small molecule drug in late July, last month, Cerley Pharmaceuticals announced that the company's clinical trial application for the new coronavirus oral drug ASC10 was approved by the State Food and Drug Administration of China.
Circular of the State Food and Drug Administration on The Issuance of the Catalogue of Generic Drug Reference Preparations (Batch 57) (No. 38 [2022
Time of Update: 2022-09-07
docx After the review and determination of the Expert Committee on the Consistency Evaluation of the Quality and Efficacy of Generic Drugs of the State Drug Administration, the Catalogue of Generic Drug Reference Preparations (The Fifty-seventh Batch) is hereby released.
FDA approves emergency use of second oral drug to treat COVID-19
Time of Update: 2022-02-24
S. Food and Drug Administration approved the first oral drug for emergency use in the treatment of new coronavirus infections on the 22nd .
Soaring 400% injection
Time of Update: 2022-02-21
Source: CDE official website, Minet database A few days ago, the CDE official website showed that the neostigmine methyl sulfate injection of Chengdu Yuandong Biopharmaceutical was accepted as a 3-type imitation .
Under centralized procurement, the price reduction of unselected original research drugs has also become a trend
Time of Update: 2021-12-27
According to data from Meinenet, in 2020, the total sales of valsartan in Chinese public medical institutions and physical pharmacies in cities in China will exceed 5 billion yuan .
Orient Pharmaceuticals: Pregabalin passed the drug GMP compliance inspection
Time of Update: 2021-08-06
On July 22, Oritech issued an announcement stating that the company learned from the Zhejiang Provincial Food and Drug Administration website that pregabalin passed the drug GMP compliance inspection results and is mainly used for the treatment of post-herpetic neuralgia and fibromyalgia .
Shanghai Pharmaceuticals Pregabalin Capsules Received U.S. FDA Approval Number
Time of Update: 2021-08-03
Pregabalin capsules original research plant for Pfizer, overseas production and sales of manufacturers are Actavis, Teva, Dr.
According to the Evaluate Pharma database, global sales of the drug will be approximately US$2.
089 billion in 2020, and US sales of approximately US$355 million .
1268 varieties, 5-year retrospective analysis: What kind of drugs can speed up review and approval
Time of Update: 2021-07-29
Data source: CPM new drug research and development monitoring database Drug priority review related support policies ● November 2015-Announcement of the State Food and Drug Administration on Soliciting Opinions on the Implementation of Priority Review and Approval for Resolving the Backlog of Drug Registration Applications (Draft for Solicitation of Opinions) (2015 No.
Promising to be the first eye drops for the treatment of presbyopia, AbbVie's innovative treatment phase 3 clinical results are positive
Time of Update: 2021-07-27
Note: The original text has been deletedReference materials: New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition.
Retrieved July 25, 2021, from https:// releases/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye- condition-301339937.
The Central Procurement of the Chinese Patent Medicine Alliance will be launched: Is the price cut coming
Time of Update: 2021-06-22
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
Roche Huntington’s ASO Phase III clinical trial stopped
Time of Update: 2021-04-27
Tominersen is an anti-nucleic acid drug that binds to Huntington mRNA and degrades this mRNA through the RNA degradation system, thus reducing the expression of toxic proteins, which may change the course of the disease.
Biogen Alzheimer's monoclonal antibody aducanumab was criticized by the FDA committee
Time of Update: 2021-04-14
According to Bojian, the data of a group of patients who received a sufficiently high dose of drug treatment showed significant benefits in terms of cognition and function, including memory, orientation, and language, as well as benefits for activities of daily living.